Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases

Journal of Medicinal Chemistry

Volumn 48, Issue 14, 2005, Pages 4628-4653

  Thompson, Andrew M ^a   Delaney, Amy M ^b   Hamby, James M ^b   Schroeder, Mel C ^b   Spoon, Teresa A ^b   Crean, Sheila M ^b   Showalter, H D Hollis ^b   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 (3,5 DIMETHOXYPHENYL) 1,6 NAPHTHYRIDIN 2 AMINE; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; AAL 993; ACETAMIDE; ALIPHATIC AMINE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; NAPHTHYRIDINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SUNITINIB; UNCLASSIFIED DRUG; UREA DERIVATIVE; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VATALANIB;

ACYLATION; ALKYLATION; AMINATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEBENZYLATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYDROGENOLYSIS; IC 50; ONCOGENE SRC; STRUCTURE ACTIVITY RELATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOTHELIAL CELLS; HUMANS; NAPHTHYRIDINES; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, FIBROBLAST GROWTH FACTOR; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; UMBILICAL VEINS; UREA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 22244491050     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0500931     Document Type: Article

References (71)

1. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 1999, 58, 17-38.
2. Brown, J. M.; Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998, 58, 1408-1416.
3. Relf, M.; LeJeune, S.; Scott, P. A. E.; Fox, S.; Smith, K.; Leek, R.; Moghaddam, A.; Whitehouse, R.; Bicknell, R.; Harris, A. L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997, 57, 963-969.
4. Campbell, S. C.; Volpert, O. V.; Ivanovich, M.; Bouck, N. P. Molecular mediators of angiogenesis in bladder cancer. Cancer Res. 1998, 58, 1298-1304.
5. Kumar, R.; Kuniyasu, H.; Bucana, C. D.; Wilson, M. R.; Fidler, I. J. Spatial and temporal expression of angiogenic molecules during tumor growth and progression. Oncol. Res. 1998, 10, 301-311.
6. Compagni, A.; Wilgenbus, P.; Impagnatiello, M.-A.; Gotten, M.; Christofori, G. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res. 2000, 60, 7163-7169.
7. Friesel, R.; Maciag, T. Fibroblast growth factor prototype release and fibroblast growth factor receptor signaling. Thromb. Haemostasis 1999, 82, 748-754.
8. Veikkola, T.; Karkkainen, M.; Claesson-Welsh, L.; Alitalo, K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000, 60, 203-212.
9. Cross, M. J.; Dixelius, J.; Matsumoto, T.; Claesson-Welsh, L. VEGF-receptor signal transduction. Trends Biochem. Sci. 2003, 28, 488-494.
10. Yoshimura, N.; Sano, H.; Hashiramoto, A.; Yamada, R.; Nakajima, H.; Kondo, M.; Oka, T. The expression and localization of fibroblast growth factor-1 (FGF-1) and FGF receptor-1 (FGFR-1) in human breast cancer. Clin. Immunol. Immunopathol. 1998, 89, 28-34.
11. Giri, D.; Ropiquet, F.; Ittmann, M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin. Cancer Res. 1999, 5, 1063-1071.
12. Wagner, M.; Lopez, M. E.; Cahn, M.; Korc, M. Suppression of fibroblast growth factor receptor signaling inhibits pancreatic cancer growth in vitro and in vivo. Gastroenterology 1998, 114, 798-807.
13. Manabe, N.; Oda, H.; Nakamura, K.; Kuga, Y.; Uchida, S.; Kawaguchi, H. Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients. Rheumatology 1999, 38, 714-720.
14. Katinioti, A. A.; Tousoulis, D.; Economou, E.; Stefanadis, C.; Trikas, A.; Tentolouris, C.; Pitsavos, C.; Androulakis, A.; Toutouzas, P. Basic fibroblast growth factor changes in response to coronary angioplasty in patients with stable angina. Int. J. Cardiol. 2002, 84, 195-199.
15. Guo, P.; Xu, L.; Pan, S.; Brekken, R. A.; Yang, S.-T.; Whitaker, G. B.; Nagane, M.; Thorpe, P. E.; Rosenbaum, J. S.; Huang, H.-J. S.; Cavenee, W. K.; Cheng, S.-Y. Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites. Cancer Res. 2001, 61, 8569-8577.
16. Yoshiji, H.; Harris, S. R.; Thorgeirsson, U. P. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res. 1997, 57, 3924-3928.
17. O'Brien, T.; Cranston, D.; Fuggle, S.; Bicknell, R.; Harris, A. L. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res. 1995, 55, 510-513.
18. Takahashi, Y.; Kitadai, Y.; Bucana, C. D.; Cleary, K. R.; Ellis, L. M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995, 55, 3964-3968.
19. Bellamy, W. T.; Richter, L.; Frutiger, Y.; Grogan, T. M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999, 59, 728-733.
20. Prewett, M.; Huber, J.; Li, Y.; Santiago, A.; O'Conner, W.; King, K.; Overholser, J.; Hooper, A.; Pytowski, B.; Witte, L.; Bohlen, P.; Hicklin, D. J. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999, 59, 5209-5218.
21. Millauer, B.; Longhi, M. P.; Plate, K. H.; Shawver, L. K.; Risau, W.; Ullrich, A.; Strawn, L. M. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 1996, 56, 1615-1620.
22. Shawver, L. K.; Lipson, K. E.; Fong, T. A. T.; McMahon, G.; Plowman, G. D.; Strawn, L. M. Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Discovery Today 1997, 2, 50-63.
23. Manley, P. W.; Bold, G.; Bruggen, J.; Fendrich, G.; Furet, P.; Mestan, J.; Schnell, C.; Stolz, B.; Meyer, T.; Meyhack, B.; Stark, W.; Strauss, A.; Wood, J. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim. Biophys. Acta 2004, 1697, 17-27.
24. Zhu, Z.; Bohlen, P.; Witte, L. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr. Cancer Drug Targets 2002, 2, 135-156.
25. Fong, T. A. T.; Shawver, L. K.; Sun, L.; Tang, C.; App, H.; Powell, T. J.; Kim, Y. H.; Schreck, R.; Wang, X.; Risau, W.; Ullrich, A.; Hirth, K. P.; McMahon, G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999, 59, 99-106.
26. Laird, A. D.; Vajkoczy, P.; Shawver, L. K.; Thurnher, A.; Liang, C.; Mohammadi, M.; Schlessinger, J.; Ullrich, A.; Hubbard, S. R.; Blake, R. A.; Fong, T. A. T.; Strawn, L. M.; Sun, L.; Tang, C.; Hawtin, R.; Tang, F.; Shenoy, N.; Hirth, K. P.; McMahon, G.; Cherrington, J. M. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 2000, 60, 4152-4160.
27. Fiedler, W.; Mesters, R.; Tinnefeld, H.; Loges, S.; Staib, P.; Duehrsen, U.; Flasshove, M.; Ottmann, O. G.; Jung, W.; Cavalli, F.; Kuse, R.; Thomalla, J.; Serve, H.; O'Farrell, A. M.; Jacobs, M.; Brega, N. M.; Scigalla, P.; Hossfeld, D. K.; Berdel, W. E. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003, 102, 2763-2767.
28. Kuenen, B. C.; Tabernero, J.; Baselga, J.; Cavalli, F.; Pfanner, E.; Conte, P. F.; Seeber, S.; Madhusudan, S.; Deplanque, G.; Huisman, H.; Scigalla, P.; Hoekman, K.; Harris, A. L. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin. Cancer Res. 2003, 9, 1648-1655.
29. Sun, L.; Liang, C.; Shirazian, S.; Zhou, Y.; Miller, T.; Cui, J.; Fukuda, J. Y.; Chu, J.-Y.; Nematalla, A.; Wang, X.; Chen, H.; Sistla, A.; Luu, T. C.; Tang, F.; Wei, J.; Tang, C. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z) -ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl) amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 2003, 46, 1116-1119.
30. Mendel, D. B.; Laird, A. D.; Xin, X.; Louie, S. G.; Christensen, J. G.; Li, G.; Schreck, R. E.; Abrams, T. J.; Ngai, T. J.; Lee, L. B.; Murray, L. J.; Carver, J.; Chan, E.; Moss, K. G.; Haznedar, J. O.; Sukbuntherng, J.; Blake, R. A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J. M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9, 327-337.
31. Wedge, S. R.; Ogilvie, D. J.; Dukes, M.; Kendrew, J.; Chester, R.; Jackson, J. A.; Boffey, S. J.; Valentine, P. J.; Curwen, J. O.; Musgrove, H. L.; Graham, G. A.; Hughes, G. D.; Thomas, A. P.; Stokes, E. S. E.; Curry, B.; Richmond, G. H. P.; Wadsworth, P. F.; Bigley, A. L.; Hennequin, L. F. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002, 62, 4645-4655.
32. Bold, G.; Altmann, K.-H.; Frei, J.; Lang, M.; Manley, P. W.; Traxler, P.; Wietfeld, B.; Bruggen, J.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Furet, P.; Hofmann, F.; Martiny-Baron, G.; Mestan, J.; Rosel, J.; Sills, M.; Stover, D.; Acemoglu, F.; Boss, E.; Emmenegger, R.; Laesser, L.; Masso, E.; Roth, R.; Schlachter, C.; Vetterli, W.; Wyss, D.; Wood, J. M. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J. Med. Chem. 2000, 43, 2310-2323.
33. Thomas, A. L.; Morgan, B.; Drevs, J.; Unger, C.; Wiedenmann, B.; Vanhoefer, U.; Laurent, D.; Dugan, M.; Steward, W. P. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin. Oncol. 2003, 30 (3, Suppl. 6), 32-38.
34. Beebe, J. S.; Jani, J. P.; Knauth, E.; Goodwin, P.; Higdon, C.; Rossi, A. M.; Emerson, E.; Finkelstein, M.; Floyd, E.; Harriman, S.; Atherton, J.; Hillerman, S.; Soderstrom, C.; Kou, K.; Gant, T.; Noe, M. C.; Foster, B.; Rastinejad, F.; Marx, M. A.; Schaeffer, T.; Whalen, P. M.; Roberts, W. G. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res. 2003, 63, 7301-7309.
35. Gingrich, D. E.; Reddy, D. R.; Iqbal, M. A.; Singh, J.; Aimone, L. D.; Angeles, T. S.; Albom, M.; Yang, S.; Ator, M. A.; Meyer, S. L.; Robinson, C.; Ruggeri, B. A.; Dionne, C. A.; Vaught, J. L.; Mallamo, J. P.; Hudkins, R. L. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-α]pyrrolo[3,4-c] carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J. Med. Chem. 2003, 46, 5375-5388.
36. Ruggeri, B.; Singh, J.; Gingrich, D.; Angeles, T.; Albom, M.; Chang, H.; Robinson, C.; Hunter, K.; Dobrzanski, P.; Jones-Bolin, S.; Aimone, L.; Klein-Szanto, A.; Herbert, J.-M.; Bono, F.; Schaeffer, P.; Casellas, P.; Bourie, B.; Pili, R.; Isaacs, J.; Ator, M.; Hudkins, R.; Vaught, J.; Mallamo, J.; Dionne, C. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res. 2003, 63, 5978-5991.
37. Hamby, J. M.; Connolly, C. J. C.; Schroeder, M. C.; Winters, R. T.; Showalter, H. D. H.; Panek, R. L.; Major, T. C.; Olsewski, B.; Ryan, M. J.; Dahring, T.; Lu, G. H.; Reiser, J.; Amar, A.; Shen, C.; Kraker, A. J.; Slintak, V.; Nelson, J. M.; Fry, D. W.; Bradford, L.; Hallak, H.; Doherty, A. M. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J. Med. Chem. 1997, 40, 2296-2303.
38. Panek, R. L.; Lu, G. H.; Dahring, T. K.; Batley, B. L.; Connolly, C.; Hamby, J. M.; Brown, K. J. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase. J. Pharmacol. Exp. Ther. 1998, 286, 569-577.
39. Dimitroff, C. J.; Klohs, W.; Sharma, A.; Pera, P.; Driscoll, D.; Veith, J.; Steinkampf, R.; Schroeder, M.; Klutchko, S.; Sumlin, A.; Henderson, B.; Dougherty, T. J.; Bernacki, R. J. Anti-angiogenic activity of selected tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest. New Drugs 1999, 17, 121-135.
40. Mohammadi, M.; Froum, S.; Hamby, J. M.; Schroeder, M. C.; Panek, R. L.; Lu, G. H.; Eliseenkova, A. V.; Green, D.; Schlessinger, J.; Hubbard, S. R. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 1998, 17, 5896-5904.
41. Thompson, A. M.; Connolly, C. J. C.; Hamby, J. M.; Boushelle, S.; Hartl, B. G.; Amar, A. M.; Kraker, A. J.; Driscoll, D. L.; Steinkampf, R. W.; Patmore, S. J.; Vincent, P. W.; Roberts, B. J.; Elliott, W. L.; Klohs, W.; Leopold, W. R.; Showalter, H. D. H.; Denny, W. A. 3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine- 2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase. J. Med. Chem. 2000, 43, 4200-4211.
42. Thompson, A. M.; Showalter, H. D. H.; Denny, W. A. Synthesis of 7-substituted 3-aryl-1,6-naphthyridin-2-amines and 7-substituted 3-aryl-1,6-naphthyridin-2(1H)-ones via diazotization of 3-aryl-1,6- naphthyridine-2,7-diamines. J. Chem. Soc., Perkin Trans. 1 2000, 1843-1852.
43. Singerman, G. M.; Kimura, R.; Riebsomer, J. L.; Castle, R. N. Synthesis of alkylaminoethanethiolsulfuric acids substituted with heterocyclic moieties. J. Heterocycl. Chem. 1966, 3, 74-78.
44. Watanabe, M.; Soai, K. Enantioselective addition of diethylzinc to aldehydes using chiral polymer catalysts possessing a methylene spacer. J. Chem. Soc., Perkin Trans, 1 1994, 837-842.
45. Sargent, M. V.; Wangchareontrakul, S. Synthesis of the cyclophane tetramethoxyturriane: a derivative of the phenolic cyclophanes of Grevillea striata R. Br. J. Chem. Soc., Perkin Trans. 1 1990, 129-132.
46. Genzer, J. D.; Huttrer, C. P.; v. Wessem, G. C. Phenoxy- and benzyloxyalkyl thiocyanates. J. Am. Chem. Soc. 1951, 73, 3159-3162.
47. Sheehan, M.; Spangler, R. J.; Djerassi, C. Mass spectrometry in structural and stereochemical problems. CCLX. Functional group interaction after electron impact. Anomalous ether cleavage in bifunctional benzyloxy ethers. J. Org. Chem. 1971, 36, 3526-3532.
48. Borjesson, L.; Csoregh, I.; Welch, C. J. Synthesis and conformational analysis of 2,9-disubstituted 1-oxaquinolizidines. J. Org. Chem. 1995, 60, 2989-2999.
49. Garegg, P. J.; Samuelsson, B. Novel reagent system for converting a hydroxy-group into an iodo-group in carbohydrates with inversion of configuration. Part 2. J. Chem. Soc., Perkin Trans. 1 1980, 2866-2869.
50. Armarego, W. L. F. Naphthyridines. Part III. Tetrahydro- and decahydro-1,5-, -1,6-, -1,7-, and -1,8-naphthyridines. J. Chem Soc. 1967, 377-383.
51. Ikemoto, N.; Schreiber, S. L. Total synthesis of (-)-hikizimycin employing the strategy of two-directional chain synthesis. J. Am. Chem. Soc. 1992, 114, 2524-2536.
52. Freifelder, M. Catalytic Hydrogenation in Organic Synthesis. Procedures and Commentary; J. Wiley & Sons: New York, 1978; pp 156-164.
53. Slotta, K. H.; Behnisch, R. Hydrocupreine aminoalkyl ethers. Chem. Ber. 1935, 68B, 754-761.
54. v. Braun, J. Knowledge about aliphatic dihalogenated compounds. Chem. Ber. 1913, 46, 1782-1792.
55. Yamaguchi, M.; Takata, T.; Endo, T. Oxidation of ω-(benzoyloxy)- alkanols with an oxoaminium salt. J. Org. Chem. 1990, 55, 1490-1492.
56. Park, M. H.; Takeda, R.; Nakanishi, K. Microscale cleavage reaction of (phenyl)benzyl ethers by ferric chloride. Tetrahedron Lett. 1987, 28, 3823-3824.
57. Fuji, K.; Ichikawa, K.; Node, M.; Fujita, E. Hard acid and soft nucleophile system. New efficient method for removal of benzyl protecting group. J. Org. Chem. 1979, 44, 1661-1664.
58. Cossy, J.; Bouzbouz, S.; Lachgar, M.; Hakiki, A.; Tabyaoui, B. Specific oxidative cleavage of allylic and benzylic benzyl ethers by using pyridinium chlorochromate. Tetrahedron Lett. 1998, 39, 2561-2564.
59. Schuda, P. F.; Cichowicz, M. B.; Heimann, M. R. A facile method for the oxidative removal of benzyl ethers: the oxidation of benzyl ethers to benzoates by ruthenium tetraoxide. Tetrahedron Lett. 1983, 24, 3829-3830.
60. Walker, D.; Hiebert, J. D. 2,3-Dichloro-5,6-dicyanobenzoquinone and its reactions. Chem. Rev. 1967, 67, 153-195.
61. Blankley, C. J.; Doherty, A. M.; Hamby, J. M.; Panek, R. L.; Schroeder, M. C.; Showalter, H. D. H.; Connolly, C. 6-Aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation. U.S. Patent 5,733,913, March 31, 1998.
62. Barvian, M.; Boschelli, D. H.; Cossrow, J.; Dobrusin, E.; Fattaey, A.; Fritsch, A.; Fry, D.; Harvey, P.; Keller, P.; Garrett, M.; La, F.; Leopold, W.; McNamara, D.; Quin, M.; Trumpp-Kallmeyer, S.; Toogood, P.; Wu, Z.; Zhang, E. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J. Med. Chem. 2000, 43, 4606-4616.
63. Palmer, B. D.; Rewcastle, G. W.; Thompson, A. M.; Boyd, M.; Showalter, H. D. H.; Sercel, A. D.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 4. Structure-activity relationships among N- and 3-substituted 2,2′-dithiobis(1H-indoles) for in vitro inhibition of receptor and nonreceptor protein tyrosine kinases. J. Med. Chem. 1995, 38, 58-67.
64. Dahring, T. K.; Lu, G. H.; Hamby, J. M.; Batley, B. L.; Kraker, A. J.; Panek, R. L. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor. J. Pharmacol. Exp. Ther. 1997, 281, 1446-1456.
65. McTigue, M. A.; Wickersham, J. A.; Pinko, C.; Showalter, R. E.; Parast, C. V.; Tempczyk-Russell, A.; Gehring, M. R.; Mroczkowski, B.; Kan, C.-C.; Villafranca, J. E.; Appelt, K. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure 1999, 7, 319-330.
66. c-arc. J. Med. Chem. 2000, 43, 3134-3147.
67. Trumpp-Kallmeyer, S.; Rubin, J. R.; Humblet, C.; Hamby, J. M.; Showalter, H. D. H. Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors. J. Med. Chem. 1998, 41, 1752-1763.
68. Garfinkel, S.; Hu, X.; Prudovsky, I. A.; McMahon, G. A.; Kapnik, E. M.; McDowell, S. D.; Maciag, T. FGF-1-dependent proliferative and migratory responses are impaired in senescent human umbilical vein endothelial cells and correlate with the inability to signal tyrosine. phosphorylation of fibroblast growth factor receptor-1 substrates. J. Cell Biol. 1996, 134, 783-791.
69. Baumgarten, H. E.; Chen, P. Y.-N.; Taylor, H. W.; Hwang, D.-R. Reactions of amines. 20. Syntheses of racemic and optically active alkylhydrazines and N-acyl-N-alkyl and N-acyl-N-arylhydrazines. J. Org. Chem. 1976, 41, 3805-3811.
70. Parast, C. V.; Mroczkowski, B.; Pinko, C.; Misialek, S.; Khambatta, G.; Appelt, K. Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis. Biochemistry 1998, 37, 16788-16801.
71. Dionne, C. A.; Crumley, G.; Beilot, F.; Kaplow, J. M.; Searfoss, G.; Ruta, M.; Burgess, W. H.; Jaye, M.; Schlessinger, J. Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors. EMBO J. 1990, 9, 2685-2692.